^
Association details:
Biomarker:BRCA1 mutation
Cancer:Prostate Cancer
Drug:Lynparza (olaparib) (PARP inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Title:

Lynparza plus abiraterone approved in Japan for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer

Published date:
08/24/2023
Excerpt:
AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone and prednisolone has been approved in Japan for the treatment of adult patients with BRCA-mutated (BRCAm) castration-resistant prostate cancer with distant metastasis (mCRPC)….This approval by the Japanese Ministry of Health, Labour and Welfare was based on a subgroup analysis of the PROpel Phase III trial which showed that Lynparza plus abiraterone demonstrated highly clinically meaningful improvements in both radiographic progression-free survival (rPFS) and overall survival (OS) versus abiraterone alone in patients with BRCA mutations.
Secondary therapy:
abiraterone acetate
Evidence Level:
Sensitive: A1 - Approval
Title:

Health Canada approves Lynparza in combination with abiraterone and prednisone or prednisolone for patients with BRCA mutated metastatic castration-resistant prostate cancer

Published date:
07/13/2023
Excerpt:
Health Canada has granted a Notice of Compliance with Conditions (NOC/c) for Lynparza® (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.
Secondary therapy:
abiraterone acetate;
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
05/31/2023
Excerpt:
...Food and Drug Administration approved olaparib (Lynparza, AstraZeneca Pharmaceuticals LP) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC), as determined by an FDA-approved companion diagnostic test.
Secondary therapy:
abiraterone acetate; abiraterone acetate
Evidence Level:
Sensitive: A1 - Approval
Title:

Lynparza approved in China for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer

Published date:
06/24/2021
Excerpt:
AstraZeneca and MSD's Lynparza (olaparib) has been granted conditional approval in China to treat adult patients with germline or somatic BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following treatment that included a new hormonal agent (abiraterone, enzalutamide).
Evidence Level:
Sensitive: A1 - Approval
Title:

Lynparza approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers

Published date:
12/28/2020
Excerpt:
AstraZeneca and MSD’s Lynparza (olaparib) has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers….The three approvals authorise Lynparza for:...the treatment of patients with BRCA gene-mutated (BRCAm) castrate-resistant prostate cancer with distant metastasis (mCRPC)...
Evidence Level:
Sensitive: A1 - Approval
Published date:
11/05/2020
Excerpt:
Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.
Evidence Level:
Sensitive: A1 - Approval
Source:
Title:

Lynparza (olaparib) Receives Health Canada Approval for the Treatment of BRCA or ATM Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

Published date:
08/21/2020
Excerpt:
Health Canada approved Lynparza (olaparib), for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent (NHA).
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
07/17/2023
Excerpt:
Prostate Cancer: Useful in certain circumstances…Olaparib/abiraterone for BRCA mutation (category 1)….
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

NICE final draft guidance recommends olaparib for early breast cancer and metastatic prostate cancer following new commercial deals

Published date:
04/06/2023
Excerpt:
The deals negotiated by NHS England and company AstraZeneca have enabled NICE to recommend olaparib as a clinically and cost-effective option:….for adults with HER2-negative, high-risk early breast cancer who have inherited faults in their BRCA1 or BRCA2 genes, after surgery and chemotherapy...and for adults with previously treated hormone-relapsed metastatic prostate cancer who have the same BRCA mutations.
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
05/21/2020
Excerpt:
Olaparib is a treatment option for patients with mCRPC and a pathogenic mutaion (germline /somatic) in a homologous recombination repair gene (BRCA1, BRCA2, ATM, BADR1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L) who have been treated with androgen-receptor therapy.
Evidence Level:
Sensitive: B - Late Trials
Title:

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

Published date:
11/14/2023
Excerpt:
In all subgroups assessed, olaparib improved outcomes versus abiraterone or enzalutamide for patients with mCRPC with BRCA alterations whose disease had progressed on previous NHA.
DOI:
10.1200/JCO.23.00339
Trial ID:
Evidence Level:
Sensitive: B - Late Trials
Title:

157O - Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Published date:
11/28/2022
Excerpt:
Pts with HRRm, including BRCAm, were balanced between treatment arms and rPFS favoured abi + ola for all biomarker subgroups, including pts with non-HRRm, HRRm and BRCAm status...Meaningful rPFS improvement of ≥5 months was observed with abi + ola vs abi + pbo in all assessed biomarker subgroups. Updated results show a continuing trend towards improved OS and support a superior clinical benefit with abi + ola vs abi + pbo as 1L therapy for pts with mCRPC.
Secondary therapy:
abiraterone acetate
Trial ID:
Evidence Level:
Sensitive: B - Late Trials
Title:

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

Published date:
11/15/2022
Excerpt:
….139 (76.8%) yielded a result and BRCA/ATM alterations were identified in 111 (79.9%). Of these, 73 patients received olaparib and 38 received control….rPFS was longer in the olaparib group versus control [median 7.4 vs. 3.5 months; hazard ratio (HR), 0.33; 95% confidence interval (CI), 0.21–0.53; nominal P < 0.0001], which is consistent with Cohort A ITT population (HR, 0.34; 95% CI, 0.25–0.47).
DOI:
https://doi.org/10.1158/1078-0432.CCR-21-3577
Trial ID:
Evidence Level:
Sensitive: B - Late Trials
Title:

Exploratory gene-by-gene analysis of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROfound.

Published date:
02/08/2021
Excerpt:
Small subgroups limit interpretation for some genes. Olaparib antitumor activity is greatest in pts with BRCA alterations, with a spectrum of clinical sensitivity to olaparib as defined by rPFS and OS across the broader population with alterations in other HRR genes.
Trial ID:
Evidence Level:
Sensitive: B - Late Trials
Title:

Exploratory gene-by-gene analysis of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROfound.

Published date:
02/08/2021
Excerpt:
Exploratory analyses in pts with alterations in BRCA1 and/or BRCA2 (BRCA, regardless of co-occurring alterations with other HRR genes) or in single genes were conducted...Evidence of olaparib antitumor activity was observed in subgroups with >10 pts...Olaparib antitumor activity is greatest in pts with BRCA alterations, with a spectrum of clinical sensitivity to olaparib as defined by rPFS and OS across the broader population with alterations in other HRR genes.
DOI:
10.1200/JCO.2021.39.6_suppl.126
Trial ID:
Evidence Level:
Sensitive: B - Late Trials
Title:

LYNPARZA® (olaparib) Receives Positive Opinion from EU CHMP for Treatment of BRCA1/2 Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Published date:
09/21/2020
Excerpt:
...AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending LYNPARZA for approval as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) who have progressed following a prior therapy that included a new hormonal agent....The CHMP’s positive opinion was based on a subgroup analysis of patients with BRCA1/2 mutations from the Phase 3 PROfound trial.
Evidence Level:
Sensitive: B - Late Trials
Title:

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

Published date:
09/20/2020
Excerpt:
Cohort A included 245 patients with at least one alteration in BRCA1, BRCA2, or ATM,...The median duration of overall survival in cohort A was 19.1 months with olaparib and 14.7 months with control therapy (hazard ratio for death, 0.69; 95% confidence interval [CI], 0.50 to 0.97; P=0.02)....Among men with metastatic castration-resistant prostate cancer who had tumors with at least one alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent, those who were initially assigned to receive olaparib had a significantly longer duration of overall survival than those who were assigned to receive enzalutamide or abiraterone plus prednisone as the control therapy, despite substantial crossover from control therapy to olaparib.
DOI:
10.1056/NEJMoa2022485
Trial ID:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

610O - Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

Published date:
09/20/2020
Excerpt:
At data cut-off (20 March 2020), median final OS in Cohort A was significantly longer with olaparib than with physician’s choice of enzalutamide or abiraterone (HR 0.69; 95% CI 0.50, 0.97; P=0.0175),...Despite extensive crossover from the control arm, olaparib conferred a statistically significant and clinically meaningful prolongation of OS vs sequential therapy with enzalutamide or abiraterone in men with mCRPC with progression on prior therapy and alterations in BRCA1, BRCA2 or ATM, with a 31% reduction in the risk for death.
Trial ID:
Evidence Level:
Sensitive: B - Late Trials
Title:

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Published date:
04/28/2020
Excerpt:
Cohort A (245 patients) had at least one alteration in BRCA1, BRCA2, or ATM...In cohort A, imaging-based progression-free survival was significantly longer in the olaparib group than in the control group (median, 7.4 months vs. 3.6 months; hazard ratio for progression or death, 0.34; 95% confidence interval, 0.25 to 0.47; P<0.001)...
DOI:
10.1056/NEJMoa1911440
Trial ID:
Evidence Level:
Sensitive: B - Late Trials
Title:

PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.

Published date:
02/13/2020
Excerpt:
Subgroup analyses of rPFS and overall survival (OS) favored ola vs pcNHA irrespective of prior taxane in Cohort A, Cohorts A+B and pts with a BRCA1 and/or BRCA2 or CDK12 alteration (Table). In the ATM subgroup hazard ratio (HR) point estimates for rPFS and OS were lower in pts who had received prior taxane vs pts who had not, but 95% CIs overlapped and pt numbers were small so data should be interpreted with caution.
Trial ID:
Evidence Level:
Sensitive: B - Late Trials
Title:

Lynparza (olaparib) granted Breakthrough Therapy designation by US FDA for treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer

Published date:
01/28/2016
Excerpt:
AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for the oral poly ADP-ribose polymerase (PARP) inhibitor Lynparza (olaparib), for the monotherapy treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer (mCRPC)...
Evidence Level:
Sensitive: B - Late Trials
New
Source:
Title:

PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations

Excerpt:
...pts with alterations in BRCA1, BRCA2 or ATM...Pts were randomized (2:1) to ola (300 mg bid)...pts with mCRPC and HRR alterations with prior NHA treatment, ola improved rPFS and ORR vs pcNHA, with a favorable trend for OS despite crossover. Safety was generally consistent with the known profile of ola.
DOI:
https://doi.org/10.1093/annonc/mdz446.007
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

Excerpt:
...Time from randomisation to second progression or clinical progression or death, whichever occurs earlier`To assess progression in pain severity domain, change in pain interference domain, and pain palliation`Functional Assessment of Cancer Therapy- Prostate Cancer (FACT-P) total score, Functional Assessment of Cancer Therapy- General (FACT-G) total score, trial outcome index, functional well-being, physical well-being, prostate cancer subscale, and Functional Assessment of Cancer Therapy (FACT) Advanced Prostate Symptom Index-6 (FAPSI-6)`Tumour samples for mutations in Breast Cancer 1 gene (BRCA1), or Breast Cancer 2 gene (BRCA2), Ataxia-telangiectasia mutated (ATM) and 12 other Homologous Recombination Repair (HRR) genes will be evaluated.`...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Excerpt:
...(The presence of a loss-of-function germline mutation in the BRCA1 and/or BRCA2 gene must be confirmed prior to consent according to local practice)....
Trial ID:
More C2 evidence
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

Excerpt:
...For enrichment stage of trial only (if necessary): Confirmation of a suspected/known deleterious mutation in a gene of interest (ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, or other DNA repair genes) via CLIA certified testing....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Excerpt:
...- All participants must have documented BRCA 1/2 mutant or other HRD+ in solid tumor, which is identified through a validated sequencing test...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Excerpt:
...Deleterious or suspected deleterious BRCA1/2 mutation in tumor tissue....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes

Excerpt:
...Histologically proven advanced cancer, either locally or metastatic, harboring a specific pathogenic genetic alteration (with the exception of breast, pancreas, or prostate cancer patients harboring a BRCA1/2 mutation and HRD ovarian cancer) 4....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

an open explorative phase II, open label study of olaparib in the treatment of advanced cancer in patients carrying a somatic or germline mutation in a homologous recombination gene.

Excerpt:
...1- Provision of informed consent prior to any study specific procedures 2- Female or male aged > 18 years 3- Histologically proven advanced cancer, either locally or metastatic, harboring a specific pathogenic genetic alteration (with the exception of breast, pancreas, ovarian or prostate cancer patients harboring a BRCA1/2 mutation) 4- No approved targeted therapy for the specific genetic alteration in the specific tumor type 5- No other genomic driven phase I, II or III trial available for the specific genomic alteration in the specific tumor type 6- Available tumor tissue for verification of the mutation by Sanger sequencing. ...
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Go to data
Title:

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Excerpt:
...Time from randomisation to second progression or clinical progression or death`To assess progression in pain severity domain, change in pain interference domain, and pain palliation`Functional Assessment of Cancer Therapy- Prostate Cancer (FACT-P) total score, Functional Assessment of Cancer Therapy- General (FACT-G) total score, trial outcome index, functional well-being, physical well-being, prostate cancer subscale, and Functional Assessment of Cancer Therapy (FACT) Advanced Prostate Symptom Index-6 (FAPSI-6)`Tumour and blood samples for mutations in Breast Cancer 1 gene (BRCA1), or Breast Cancer 2 gene (BRCA2), Ataxia-telangiectasia mutated (ATM) and 12 other Homologous Recombination Repair (HRR) genes will be evaluated.`...
Trial ID:
Less C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

MP11-16: Prostate-specific antigen analyses in PROpel: abiraterone and olaparib versus abiraterone and placebo as first-line therapy for metastatic castration-resistant prostate cancer

Published date:
03/31/2023
Excerpt:
In this exploratory analysis, 1L mCRPC treatment with abi and ola resulted in higher PSA response rates and prolonged time to PSA progression vs abi and pbo in all pts, with more pronounced improvements in the HRRm and BRCAm subgroups.
Secondary therapy:
abiraterone acetate
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/ 2 Mutation: Results From the TAPUR Study

Published date:
02/08/2023
Excerpt:
Thirty patients with mCRPC with BRCA1/2 mutations were treated with olaparib. The disease control rate was 69% (95% CI, 51 to 81), and the objective response rate was 58% (95% CI, 37 to 77). The median radiographic progression-free survival and the median overall survival were 38.4 (95% CI, 16.3 to 52.1) weeks and 76.4 (95% CI, 49.3 to 106.0) weeks, respectively.
DOI:
10.1200/PO.22.00505
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

1357O - Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Published date:
09/05/2022
Excerpt:
Sensitivity analysis of rPFS by blinded independent central review was consistent. At DCO2 (14/03/22) rPFS was consistent with the primary analysis (25.0 vs 16.4 months; HR 0.67, 95% CI 0.56–0.81). A trend towards improved OS with abi + ola vs abi + pbo continued (maturity 40%; HR 0.83; 95% CI 0.66–1.03). Safety and tolerability results remained stable.Meaningful rPFS improvement of ≥5 months was observed with abi + ola vs abi + pbo in all assessed biomarker subgroups. Updated results show a continuing trend towards improved OS and support a superior clinical benefit with abi + ola vs abi + pbo as 1L therapy for pts with mCRPC.
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects

Published date:
05/26/2022
Excerpt:
≥50% PSA decline was 79%, 67%, and 85% of pts in Arms 1, 2, and 3, respectively. Median PSA nadir (ng/mL) (95% CI) Arms 1-3: 2.17 (0.44, 49.27), 3.10 (0.83, 12.01), and 0.50 (0.10, 2.13), respectively. In mCRPC pts with inactivating BRCA1, BRCA2 and/or ATM alterations Abi/pred + olaparib was well tolerated and resulted in longer PFS and better PSA response vs either agent alone.
DOI:
10.1200/JCO.2022.40.16_suppl.5018
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer

Published date:
08/26/2020
Excerpt:
In patients with at least one alteration in BRCA1, BRCA2, or ATM (Cohort A), the primary endpoint of PFS was significantly longer for the olaparib group (7.4 months) than the control group (3.6 months) with HR = 0.34, 95% CI, 0.25–0.47; p < .001.
DOI:
10.1080/15384047.2020.1809913
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Olaparib monotherapy in pretreated patients with BRCA1/2 alterations: Results of a DRUP trial cohort.

Published date:
05/13/2020
Excerpt:
Nine different cancer types were included: prostate (n=11), breast (n=4), ovarian (n=2), pancreatic (n=3), colorectal (n=2), biliary tract (n=2), kidney (n=1), adrenal gland (n=1) and endometrial (n=1). The primary endpoint was clinical benefit (CB: objective response or stable disease (SD) ≥ 16 weeks). CB was observed in pts with both somatic and germline BRCA alterations and across tumor types.
DOI:
10.1200/JCO.2020.38.15_suppl.3633
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Published date:
05/13/2020
Excerpt:
Nine pts with OR and 8 with SD16+ were observed for DC and OR rates of 68% (90% CI: 53% - 77%) and 36% (95% CI: 18% - 57%), respectively.
DOI:
"10.1200/JCO.2020.38.15_suppl.556 "
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations

Excerpt:
Patients with BRCA1/2 mutations had median PFS of 12.3 mo versus 2.4 mo for those with ATM mutations...Men with mCRPC harboring ATM mutations experienced inferior outcomes to PARP inhibitor therapy compared to those harboring BRCA1/2 mutations.
DOI:
https://doi.org/10.1016/j.eururo.2019.02.002
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Excerpt:
Next-generation sequencing identified homozygous deletions, deleterious mutations, or both in DNA-repair genes--including BRCA1/2, ATM, Fanconi's anemia genes, and CHEK2--in 16 of 49 patients who could be evaluated (33%)...Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate.
DOI:
10.1056/NEJMoa1506859
Trial ID: